Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on OncoZenge’s SEK33.3m rights issue, which is intended to strengthen the balance sheet and provide funding for the continued execution of the pivotal Phase III BEAM-Pain trial and subsequent MAA preparations.</li><li>While the issue is meaningfully dilutive for non-participating shareholders, we view the it as appropriate given the company’s transition into full clinical execution and towards potential European commercialization.</li></ul>

Redeye comments on OncoZenge’s SEK33.3m rights issue, which is intended to strengthen the balance sheet and provide funding for the continued execution of the pivotal Phase III BEAM-Pain trial and subsequent MAA preparations.While the issue is meaningfully dilutive for non-participating shareholders, we view the it as appropriate given the company’s transition into full clinical execution and towards potential European commercialization.

OncoZenge: SEK33.3m Rights issue announced

Oncozenge

OncoZenge: SEK33.3m Rights issue announced